trending Market Intelligence /marketintelligence/en/news-insights/trending/653ilzCWqtt09wovovX6hw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Medivir completes sale of pharma unit to Karo Pharma

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Medivir completes sale of pharma unit to Karo Pharma

Medivir AB completed the divestment of its unit BioPhausia AB to Stockholm-based Karo Pharma AB.

The Medivir board will propose that net proceeds from the sale, about 870 million Swedish kronor, or 32 kronor per share, be transferred to Medivir shareholders through a voluntary share redemption offer. The board will convene a general meeting by early January 2017.

Stockholm-based Medivir is a molecular diagnostics company that develops epigenetic tests for cancer assessment.

As of Dec. 15, US$1 was equivalent to 9.38 Swedish kronor.